# A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)

> **NCT01055340** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Oxyntomodulin (OXM)
- **DRUG:** Comparator: Oxyntomodulin (OXM)
- **DRUG:** Comparator: Placebo [ hemaccel-containing saline]

## Key facts

- **NCT ID:** NCT01055340
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01055340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01055340, "A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01055340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*